Beijing Scitop Bio-tech Co: Revenue up 20.85%, net profit stable, probiotics and microecological agents drive growth
· Issued by Beijing Scitop Bio-tech Co., Ltd. Class A
Revenue grew 20.85% to ¥365.92 million, with net profit stable at ¥94.52 million. Probiotics led growth, while microecological agents surged 121%. Major R&D and production investments continue, with a ¥1.00 per 10 shares dividend declared.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Earlier from Beijing Scitop Bio-tech Co., Ltd. Class A
